|
Match
|
Document |
Document Title |
|
|
US20100004156 |
Small Compounds That Correct Protein Misfolding and Uses Thereof
The invention features compositions and methods that are useful for treating or preventing a protein conformation disease in a subject by correcting misfolded proteins in vivo. In addition, the...
|
|
|
US20100004316 |
MULTIFUNCTIONAL CARRIERS FOR THE DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF
Described herein are multifunctional compounds useful as devices for the delivery of nucleic acids to cells. Also described herein are methods for using the multifunctional compounds.
|
|
|
US20100004234 |
SPECIFIC KINASE INHIBITORS
Resorcylic acid lactones having a C5-C6 cis double bond and a ketone at C7 and other compounds capable of Michael adduct formation are potent and stable inhibitors of a subset of protein kinases...
|
|
|
US20100003299 |
RNAi Methods and Compositions for Stimulating Proliferation of Cells with Adherent Functions
Described herein are methods and compositions for stimulating proliferation of cells that express adherent junctions and cease proliferation, for example, human corneal endothelial cells, by...
|
|
|
US20100004304 |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF MALIGNANT MELANOMA, BREAST, PROSTATE, COLON, PAPILLARY THYROID AND PANCREATIC CANCER
It is now recognized that chronic inflammation is an important risk factor for the development of cancer. The proinflammatory cytokine IL-6 is implicated in cancer because it is important for the...
|
|
|
US20100003229 |
Nuclear telomerase reverse transcriptase variant
The present invention is directed to a novel variant of human telomerase reverse transcriptase (S16AhTERT), which displays properties distinct from those of wildtype telomerase reverse...
|
|
|
US20100004333 |
COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISORDERS
The present invention relates to compounds and methods for the treatment of cardiovascular diseases and disorders. Compounds according to the present invention may comprise an optionally...
|
|
|
US20090325949 |
5 HT RECEPTOR MEDIATED NEUROGENESIS
The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes...
|
|
|
US20090328259 |
Polypeptides having endoglucanase activity and polynucleotides encoding same
The present invention relates to isolated polypeptides having endoglucanase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs,...
|
|
|
US20090326041 |
COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF SGLT2
The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense...
|
|
|
US20090325882 |
CHAPERONIN 10 MODULATION OF TOLL-LIKE RECEPTOR-INDUCIBLE CYTOKINE AND CHEMOKINE SECRETION
Methods of use of Chaperonin 10 (Cpn10) are provided for regulating Toll-like receptor signaling and/or Toll-like receptor inducible immunomodulator secretion. Cpn10 negatively regulates Toll-like...
|
|
|
US20090326020 |
COMPOUNDS FOR TREATMENT OF CANCER
Compounds according to formula (I) are disclosed
where Q is S, N, or O; X is optional, and can be O═, S═, ═N—NH 2 , ═N—OH, or —OH; Y is optional and can be —N(H)—, O, or C 1 ...
|
|
|
US20090325294 |
SINGLE PLURIPOTENT STEM CELL CULTURE
The present invention relates to the field of pluripotent stem cell culture and methods facilitate pluripotent stem cell culture at industrial levels.
|
|
|
US20090326043 |
Method and Compound for Antiviral (HIV) Therapy
Disclosed is an anti-viral therapeutic that inactivates the Human Immunodeficiency Virus (HIV) RNA by siDNA. The siDNA antiviral therapeutic is effective in the treatment and inactivation of cell...
|
|
|
US20090324556 |
Mutated immunogenic peptides derived from R9M, polynucleotides coding for same and therapeutic uses thereof
The invention concerns the optimization of the wild R9M peptide and the use of the resulting peptides for therapeutic vaccination and/or preventive vaccination against leukaemia in humans. More...
|
|
|
US20090325213 |
DIAGNOSTIC AND THERAPEUTIC APPLICATION OF CTL AND NK FUNCTIONALLY SELECTED CELLS
The invention proposes a novel therapeutic and diagnostic methodology based on the use of effector cells (for example CTL and NK cells) selected for being able to induce lysis in target cells. In...
|
|
|
US20090324597 |
ULBP antibodies
The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides,...
|
|
|
US20090326049 |
BLOCKING OLIGOS FOR INHIBITION OF MICRORNA AND SIRNA ACTIVITY AND USES THEREOF
The present invention relates to methods of identifying sites in the 3′- and/or 5′-UTR of mRNA involved in the binding of miRNA and/or siRNA to their target sites and nucleic acids designed to...
|
|
|
US20090324651 |
Methods for Stimulating an Immune Response Using Bacterial Antigen Delivery System
The invention relates to the use of the type III secretion system of bacteria to stimulate immune responses against tumor antigen(s) for treating antigen-loss variant tumors. Methods are provided...
|
|
|
US20090326051 |
Modulation of gene expression through endogenous small RNA targeting of gene promoters
Gene expression can be selectively regulated by endogenous miRNAs that target promoters of genes. Altering of the activity of these promoter-targeting miRNAs with single-stranded complementary...
|
|
|
US20090325867 |
RECEPTOR-SPECIFIC TUMOUR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND (TRAIL) VARIANTS
The invention relates to a tumour necrosis factor- (TNF-) related apoptosis-inducing ligand (TRAIL) which is capable of selectively signalling through death receptor 4 (DR4), comprising Y at...
|
|
|
US20090325931 |
USE OF CDK INHIBITORS FOR THE TREATMENT OF GRANULOCYTE MEDIATED DISORDERS
Described herein is the use of CDK inhibitors such as roscovitine for inducing apoptosis of granulocytes, for example neutrophils. Their use for treating inflammatory diseases is also provided.
|
|
|
US20090325897 |
DESIGNER THERAPY OF PANCREATIC TUMORS
Chemotherapeutic and Radiation sensitizing agents which target tumor cells, specifically, based on the elevation of enzyme pathways, provide highly selective drug therapy. These agents are combined...
|
|
|
US20090325887 |
PEPTIDES AND REGULATION OF CALCIUM CHANNELS
Calcium channels can be regulated by natural gamma proteins. Herein we disclose embodiments of compositions and methods, particularly involving short peptides which are capable of regulating...
|
|
|
US20090324575 |
LYSOSOMAL PHOSPHOLIPASE A2 (LPLA2) ACTIVITY AS A DIAGNOSTIC AND THERAPEUTIC TARGET FOR IDENTIFYING AND TREATING SYSTEMIC LUPUS ERYTHEMATOSIS
The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification...
|
|
|
US20090326042 |
COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF CRP
The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense...
|
|
|
US20090325291 |
METHOD OF PREPARING siRNAs FOR SELECTIVE INHIBITION OF TARGET mRNA ISOTYPES
A method of preparing siRNAs for selective inhibition of target mRNA isotypes comprises: dividing target mRNA isotypes intended to inhibit the expression thereof and non-target mRNA isotypes from...
|
|
|
US20090325868 |
Materials And Methods For FOXP3 Tumor Suppression
Provided herein are methods of treating a cancer in a subject comprising administering a FOXP3 protein, a nucleic acid encoding a FOXP3 protein, or an inducing compound which induces FOXP3 protein...
|
|
|
US20090324602 |
ANTI-FN14 ANTIBODIES AND USES THEREOF
Antibodies and antibody fragments that bind to the receptor Fn14 and induce or enhance cell killing of Fn14-expressing cancer cells are disclosed. Also disclosed are methods of using the antibodies...
|
|
|
US20090325876 |
USE OF LIPID CONJUGATES IN THE TREATMENT OF DISEASES ASSOCIATED WITH VASCULATURE
This invention provides for the use of compounds represented by the structure of the general formula (A):
wherein L is a lipid or a phospholipid, Z is either nothing, ethanolamine, serine,...
|
|
|
US20090324608 |
Novel human protein kinase, phosphatase, and protease family members and uses thereof
The invention provides isolated nucleic acids molecules, designated 53070, 15985, 26583, 21953, m32404, 14089, and 23436 nucleic acid molecules, which encode novel human protein kinase family...
|
|
|
US20090325292 |
Functional polyglycolide nanoparticles derived from unimolecular micelles
Poly(glycolide) polymers are disclosed. The polymers generally include a glycolide-based polymer backbone that includes one or more functional groups such as alkynyl groups, hydrophilic organic...
|
|
|
US20090317855 |
RECEPTOR-MEDIATED DELIVERY: COMPOSITIONS AND METHODS
Compositions and methods for delivering an agent to a cell comprising a prolactin receptor are provided. Also provided is a method of inhibiting a breast, ovarian or prostate cancer cell, where the...
|
|
|
US20090318535 |
BETA -TrCP1, BETA -TrCP2 AND RSK1 OR RSK2 INHIBITORS AND METHODS FOR SENSITIZING TARGET CELLS TO APOPTOSIS
The invention relates to modulating BimEL levels (Bcl-2-Interacting Mediator of cell death, Extra Long isoform) to sensitize cancer cells to cell death or apoptosis. In certain embodiments, the...
|
|
|
US20090317908 |
HIGHLY PACKED POLYCATIONIC AMMONIUM, SULFONIUM AND PHOSPHONIUM LIPIDS
The present invention discloses highly packed polycationic ammonium, sulfonium and phosphonium lipid compounds useful for making lipid aggregates for delivery of macromolecules and other compounds...
|
|
|
US20090317406 |
Phosphorylation of tau by abl
Methods of diagnosing a tauopathy and predicting whether a subject will develop a tauopathy are provided. Also provided are antibody preparations that specifically bind to tau phosphorylated at...
|
|
|
US20090317368 |
B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE
The invention provides novel polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the...
|
|
|
US20090318338 |
METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION BY MODULATING KRC ACTIVITY
This invention demonstrates that KRC molecules have multiple important functions as modulating agents in regulating a wide variety of cellular processes including bone formation and mineralization....
|
|
|
US20090318409 |
PYRROLIDINE INHIBITORS OF IAP
The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I:
wherein A, Q, X 1 , X 2 , Y, R 1 ,...
|
|
|
US20090317907 |
Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs
Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding...
|
|
|
US20090317444 |
PROCESS FOR CELL PROLIFERATION
In vitro process for the proliferation or culture of conjunctive tissue cells selected from the group consisting of chondrocytes, osteoblasts, chondroprogenitor cells, osteoprogenitor cells,...
|
|
|
US20090318352 |
Materials and Methods Involving Hybrid Vascular Endothelial Growth Factor DNAs and Proteins
The present invention provides polypeptides that bind cellular receptors for vascular endothelial growth factor polypeptides; polynucleotides encoding such polypeptides; compositions comprising the...
|
|
|
US20090317906 |
GENE SILENCING USING SENSE DNA AND ANTISENSE RNA HYBRID CONSTRUCTS COUPLED TO PEPTIDES FACILITATING THE UPTAKE INTO CELLS
The present invention generally relates to gene silencing using sense DNA (sDNA)-antisense RNA (aRNA) hybrids wherein the sense DNA strand is coupled to a peptide which facilitates the uptake of...
|
|
|
US20090317811 |
TWO PORE CHANNELS AS REGULATORS OF PROLIFERATION IN CANCER
The present invention relates to the discovery that two pore K+ channel (2PK) gene expression is increased in tumors and tumor cell lines, especially prostate tumor cells. The present invention...
|
|
|
US20090317397 |
Soluble CTLA4 mutant molecules and uses thereof
The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing...
|
|
|
US20090318367 |
Use of SH2 STAT3/STAT1 Peptidomimetics as Anticancer Drugs
The subject invention concerns compositions and methods for blocking cancer cell growth or proliferation and/or inducing cancer cell death. Compositions of the present invention are peptidomimetics...
|
|
|
US20090312238 |
Protection Against Oxidative Damage in Cells
The present invention relates to the use of MT as a reducing system for the Msr enzymes and other oxioreductase enzymes which form similar intermediates. Specifically, the invention provides for a...
|
|
|
US20090312397 |
RNAi Modulation Of ApoB And Uses Thereof
The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified...
|
|
|
US20090311784 |
CYTOTOXIC RIBONUCLEASE VARIANTS
This invention relates to cytotoxic variants of human ribonuclease 1 (RNase 1) identified through analysis of the interaction between RNase 1 and the human ribonuclease inhibitor (hRI) as defined...
|
|
|
US20090311786 |
Levels and/or Sustainability of DNA-based Gene Expression
The invention encompasses methods for improving the level and/or sustainability of expression for a target nucleic acid in a eukaryotic cell comprising: (a) modifying the target nucleic acid to...
|